secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2026-09-10T21:02:18+00:00
Accession:  0001193125-26-388010
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk appoints Vijay Iyengar, MD, to board; board expands to 10
-------------------------------------------------------------------

- Board expanded from 9 to 10; Iyengar appointed Class III director effective Sept 9, 2026, term to 2029 annual meeting.
- Iyengar served as EVP at Incyte (INCY) from 2016-2025; led growth from ~$1B to >$4B revenue, launched 5 brands.
- As non-employee director, receives $40k annual retainer and initial option grant of 76,080 shares vesting over 3 years.
- Press release dated Sept 10, 2026 attached as Exhibit 99.1; no related-party transactions or family relationships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/0001193125-26-388010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/d160342d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-388010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer